Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (98)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (5)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (297)
  2. Department of Medicine (297)
  3. Hematologic Malignancies, Division of (297)
  4. Myeloma (297)
  5. Survivorship Research (216)
  6. Hematologic Malignancies Research (212)

More Groups

People
  1. Neha Korde (191)
  2. Alexander Lesokhin (170)
  3. Hani Hassoun (163)
  4. Sergio Giralt (161)
  5. Malin Hultcrantz (158)
  6. Heather Landau (147)

More People

Years
  1. 2025 (13)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (96)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. Blood Cancer Journal (12)
  5. JAMA Oncology (12)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (107)
  2. Elsevier Inc. (71)
  3. Nature Publishing Group (26)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Journal Article

    Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
    Research Letter

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the Nutrition Prevention (NUTRIVENTION) study
    Meeting Abstract

    Shah, U. A.; Alicea, D.; Adintori, P. A.; Burge, M.; Blaslov, J.; Derkach, A.; Mailankody, S.; Korde, N.; Tan, C.; Hultcrantz, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Liedtke, M.; Sidana, S.; Matous, J. V.; Chhabra, S.; Oluwole, O. O.; Malik, S. A.; Kumar, S.; Nath, R.; Anwer, F.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Rational targets in systemic AL amyloidosis
    Meeting Abstract

    Bal, S.; Dogan, A.; Hassoun, H.; Mailankody, S.; Giralt, S. A.; Landau, H. J.
    Blood (2021)

    Fulltext@MSK | Save
  • Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel)
    Meeting Abstract

    Costa, L. J.; Mailankody, S.; Shaughnessy, P.; Hari, P.; Kaufman, J. L.; Larson, S. M.; Dingli, D.; Lee, K.; Conte, K.; DeVries, T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save